To investigate the therapeutic potential of KAI1 for inhibiting cancer growth in an in vivo mouse model, we subcutaneously transplanted B16 and PC3 (human prostate cancer cells) with and without KAI1 supplementation (combination of two strategies, firstly, rhKAI1 to bind and sequester VEGF or PDGF and, secondly, supernatant from Kai1-O/E PCs containing Lif to inhibit angiogenesis). This evidence concerns the gene CD82 and prostate cancer.